Heloisa P. Soares, MD, PhD

Journal Article

1. Kamboj M, Bohlke K, Baptiste DM, Dunleavy K, Fueger A, Jones L, Kelkar AH, Law LY, LeFebvre KB, Ljungman P, Miller ED, Meyer LA, Moore HN, Soares HP, Taplitz RA, Woldetsadik ES, Kohn EC (2024). Vaccination of Adults With Cancer: ASCO Guideline. J Clin Oncol, 42(14), 1699-1721. (Read full article)
2. Wilbur HC, Soares HP, Azad NS (2024). Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations. Hepatology. (Read full article)
3. Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK (2023). Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. J Clin Oncol, JCO2301529. (Read full article)
4. Mosley SA, Cicali E, Del Cueto A, Portman DG, Donovan KA, Gong Y, Langaee T, Gopalan P, Schmit J, Starr JS, Silver N, Chang YD, Rajasekhara S, Smith JE, Soares HP, Clare-Salzler M, Starostik P, George TJ, McLeod HL, Fillingim RB, Hicks JK, Cavallari LH (2023). CYP2D6-guided opioid therapy for adults with cancer pain: a randomized implementation clinical trial. Pharmacotherapy. (Read full article)
5. Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BR, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, Reidy-Lagunes DL, Soares HP, Strosberg JR, Kohn EC, Kunz PL, NET CTPM participants (2022). Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Natl Cancer Inst, 115(9), 1001-1010. (Read full article)
6. Florou V, Elliott A, Bailey MH, Stone D, Affolter K, Soares HP, Nevala-Plagemann C, Scaife C, Walker P, Korn WM, Lou E, Shroff RT, Hosein PJ, Garrido-Laguna I (2022). Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC. Clin Cancer Res, 29(17), 3408-3417. (Read full article)
7. Marsiglio J, McPherson JP, Kovacsovics-Bankowski M, Jeter J, Vaklavas C, Swami U, Grossmann D, Erickson-Wayman A, Soares HP, Kerrigan K, Gibson B, Doherty JA, Hyngstrom J, Hardikar S, Hu-Lieskovan S (2023). A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome. Front Immunol, 14, 1229823. (Read full article)
8. Leiter RE, Varas MTB, Miralda K, Muneton-Castano Y, Furtado G, Revette A, Cronin C, Soares HP, Lopez A, Hayman LL, Lindsay AC, Schrag D, Enzinger AC (2023). Adaptation of a Multimedia Chemotherapy Educational Intervention for Latinos: Letting Patient Narratives Speak for Themselves. J Cancer Educ, 38(4), 1353-1362. (Read full article)
9. Florou V, Floudas CS, Maoz A, Naqash AR, Norton C, Tan AC, Sokol ES, Frampton G, Soares HP, Puri S, Swami U, Wilky B, Hosein P, Trent J, Lopes GL, Park W, Garrido-Laguna I (2023). Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden. J Immunother Cancer, 11(8). (Read full article)
10. Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovitz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA (2023). Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Endocr Relat Cancer, 30(8). (Read full article)
11. Okwundu N, Weil CR, Soares HP, Fine GC, Cannon DM (2023). Case report: Efficacy of lutetium-177 oxodotreotide for neuroendocrine tumor with central nervous system metastases. Front Nucl Med, 3, 1074948. (Read full article)
12. Leiter RE, Varas MTB, Miralda K, Muneton-Castano Y, Furtado G, Revette A, Cronin C, Soares HP, Lopez A, Hayman LL, Lindsay AC, Schrag D, Enzinger AC (2023). Adaptation of a Multimedia Chemotherapy Educational Intervention for Latinos: Letting Patient Narratives Speak for Themselves. J Cancer Educ, 38(4), 1353-1362. (Read full article)
13. Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, Giordano T, Halfdanarson TR, Halperin D, He J, Heaney A, Heslin MJ, Kandeel F, Kardan A, Khan SA, Kuvshinoff BW, Lieu C, Miller K, Pillarisetty VG, Reidy D, Salgado SA, Shaheen S, Soares HP, Soulen MC, Strosberg JR, Sussman CR, Trikalinos NA, Uboha NA, Vijayvergia N, Wong T, Lynn B, Hochstetler C (2021). Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 19(7), 839-868. (Read full article)
14. Eads JR, Reidy-Lagunes D, Soares HP, Chan JA, Anthony LB, Halfdanarson TR, Naraev BG, Wolin EM, Halperin DM, Li D, Pommier RF, Zacks JS, Morse MA, Metz DC, from the Carcinoid Syndrome Control Collaborative (2020). Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors. Pancreas, 49(9), 1123-1130. (Read full article)
15. Kim R, Sanoff H, Poklepovic A, Soares H, Kim J, Lyu J, Liu Y, Kim D (2020). A multi-institutional phase II trial of regorafenib in refractory advanced biliary tract cancer. Accepted.    . Cancer.
16. Bergslang E, Halperin D, Dillon, J, Dasari A, Kunz P, Soares HP, Pryma D, Hope T, Soulen M, Mailmain J, Howe, J (2020). NANETS Guide for Neuroendocrine Tumor Patient Healthcare Providers during COVID-19" (the "Work"). Accepted. Pancreas.
17. Al-Toubah T, Schell MJ, Cives M, Zhou JM, Soares HP, Strosberg JR (2019). A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms. Neuroendocrinology, 110(5), 377-383. (Read full article)
18. Saif MW, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Ramirez RA, Halfdanarson TR, Beveridge TJR, Mirakhur B, Nagar SP, Soares HP (2019). Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. J Gastrointest Oncol, 10(4), 647-687.
19. Mahipal A, Tella SH, Kommalapati A, Goyal G, Soares H, Neuger A, Copolla D, Kim J, Kim R (2018). Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. Invest New Drugs, 37(3), 473-481. (Read full article)
20. Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, El-Khoueiry A, Feng M, Katz MHG, Primrose J, Soares HP, Valle J, Maithel SK (2019). Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol, 37(12), 1015-1027. (Read full article)
21. Nemunaitis JM, Brown-Glabeman U, Soares H, Belmonte J, Liem B, Nir I, Phuoc V, Gullapalli RR (2018). Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico. BMC Cancer, 18(1), 665. (Read full article)
22. Mosley SA, Hicks JK, Portman DG, Donovan KA, Gopalan P, Schmit J, Starr J, Silver N, Gong Y, Langaee T, Clare-Salzler M, Starostik P, Chang YD, Rajasekhara S, Smith JE, Soares HP, George TJ Jr, McLeod HL, Cavallari LH (2018). Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial. Contemp Clin Trials, 68, 7-13. (Read full article)
23. Cives M, Anaya DA, Soares H, Coppola D, Strosberg J (2017). Analysis of Postoperative Recurrence in Stage I-III Midgut Neuroendocrine Tumors. J Natl Cancer Inst, 110(3), 282-289. (Read full article)
24. Wainberg ZA, Alsina M, Soares HP, Braa I, Britten CD, Del Conte G, Ezeh P, Houk B, Kern KA, Leong S, Pathan N, Pierce KJ, Siu LL, Vermette J, Tabernero J (2017). A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Target Oncol, 12(6), 775-785. (Read full article)
25. Cives M, Soares HP, Strosberg J (2016). Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Curr Opin Oncol, 28(4), 359-66. (Read full article)
26. Wainberg ZA, Soares HP, Patel R, DiCarlo B, Park DJ, Liem A, Wang HJ, Yonemoto L, Martinez D, Laux I, Brennan M, Hecht JR (2015). Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers. Cancer Chemother Pharmacol, 76(1), 61-7. (Read full article)
27. Soares HP, Ming M, Mellon M, Young SH, Han L, Sinnet-Smith J, Rozengurt E (2015). Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. Mol Cancer Ther, 14(4), 1014-23. (Read full article)
28. Ming M, Sinnett-Smith J, Wang J, Soares HP, Young SH, Eibl G, Rozengurt E (2014). Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells. PLoS One, 9(12), e114573. (Read full article)
29. Rozengurt E, Soares HP, Sinnet-Smith J (2014). Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol Cancer Ther, 13(11), 2477-88. (Read full article)
30. Soares HP, Bayraktar S, Blaya M, Lopes G, Merchan J, Macintyre J, Mayo C, Green MR, Silva O, Levi J, Walker G, Rocha-Lima CM (2014). A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Cancer Chemother Pharmacol, 73(4), 839-45. (Read full article)
31. Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E (2013). Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS One, 8(2), e57289. (Read full article)
32. Djulbegovic B, Kumar A, Glasziou PP, Perera R, Reljic T, Dent L, Raftery J, Johansen M, Di Tanna GL, Miladinovic B, Soares HP, Vist GE, Chalmers I (2012). New treatments compared to established treatments in randomized trials. Cochrane Database Syst Rev, 10, MR000024. (Read full article)
33. Mhaskar R, Djulbegovic B, Magazin A, Soares HP, Kumar A (2012). Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. J Clin Epidemiol, 65(6), 602-9. (Read full article)
34. Djulbegovic B, Kumar A, Magazin A, Schroen AT, Soares H, Hozo I, Clarke M, Sargent D, Schell MJ (2010). Optimism bias leads to inconclusive results-an empirical study. J Clin Epidemiol, 64(6), 583-93. (Read full article)
35. Soares HP, Lutzky J (2010). Velimogene aliplasmid. Expert Opin Biol Ther, 10(5), 841-51. (Read full article)
36. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, STOPIT-2 Study Group, Flynn DN, Elamin MB, Murad MH, Abu Elnour NO, Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, Schnemann H, Cook DJ, Lutz K, Ribic CM, Vale N, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Bucher HC, Nordmann AJ, Raatz H, da Silva SA, Tuche F, Strahm B, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Karanicolas PJ, Burns KE, Vandvik PO, Coto-Yglesias F, Chrispim PP, Ramsay T (2010). Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA, 303(12), 1180-7. (Read full article)
37. Briel M, Lane M, Montori VM, Bassler D, Glasziou P, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Culebro CR, da Silva SA, Flynn DN, Elamin MB, Strahm B, Murad MH, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Abu Elnour NO, You JJ, Karanicolas PJ, Bucher HC, Lampropulos JF, Nordmann AJ, Burns KE, Mulla SM, Raatz H, Sood A, Kaur J, Bankhead CR, Mullan RJ, Nerenberg KA, Vandvik PO, Coto-Yglesias F, Schnemann H, Tuche F, Chrispim PP, Cook DJ, Lutz K, Ribic CM, Vale N, Erwin PJ, Perera R, Zhou Q, Heels-Ansdell D, Ramsay T, Walter SD, Guyatt GH (2009). Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2). Trials, 10, 49. (Read full article)
38. Trufelli DC, Bensi CG, Garcia JB, Narahara JL, Abro MN, Diniz RW, Miranda Vda C, Soares HP, Del Giglio A (2008). Burnout in cancer professionals: a systematic review and meta-analysis. Eur J Cancer Care (Engl), 17(6), 524-31. (Read full article)
39. Djulbegovic B, Kumar A, Soares HP, Hozo I, Bepler G, Clarke M, Bennett CL (2008). Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med, 168(6), 632-42. (Read full article)
40. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF (2008). Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med, 49(3), 480-508. (Read full article)
41. Tanvetyanon T, Soares HP, Djulbegovic B, Jacobsen PB, Bepler G (2007). A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol, 2(12), 1091-7. (Read full article)
42. Rocha-Lima CM, Soares HP, Raez LE, Singal R (2007). EGFR targeting of solid tumors. Cancer Control, 14(3), 295-304. (Read full article)
43. Behera M, Kumar A, Soares HP, Sokol L, Djulbegovic B (2007). Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. Cancer Control, 14(2), 160-6. (Read full article)
44. Kumar A, Soares HP, Balducci L, Djulbegovic B, National Cancer Institute (2007). Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol, 25(10), 1272-6. (Read full article)
45. Soares HP, Kumar A, Djulbegovic B (2006). Evidence profiles for breast cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev, 33(1), 87-9. (Read full article)
46. Soares HP, Kumar A, Djulbegovic B (2006). Evidence profiles for lung cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev, 32(8), 652-5. (Read full article)
47. Djulbegovic B, Soares HP, Kumar A (2006). What kind of evidence do patients and practitioners need: evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms. Cancer Treat Rev, 32(7), 572-6. (Read full article)
48. Kumar A, Soares HP, Djulbegovic B (2006). Evidence profiles for colo-rectal cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev, 32(7), 577-80. (Read full article)
49. Kumar A, Soares HP (2006). Salvage radiotherapy increases survival in people with residual disease after chemotherapy for advance diffuse large cell lymphoma. Cancer Treat Rev, 32(6), 487-90. (Read full article)
50. Kumar A, Soares H, Wells R, Clarke M, Hozo I, Bleyer A, Reaman G, Chalmers I, Djulbegovic B, Childrens Oncology Group (2005). Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group. BMJ, 331(7528), 1295. (Read full article)
51. Soares HP, Kumar A, Daniels S, Swann S, Cantor A, Hozo I, Clark M, Serdarevic F, Gwede C, Trotti A, Djulbegovic B (2005). Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA, 293(8), 970-8. (Read full article)
52. Kumar A, Soares H, Serdarevic F (2005). Totality of evidence: one of the keys to better oncology management. J Oncol Manag, 14(1), 12-4. (Read full article)
53. Weinschenker P, Soares HP, Clark O, Del Giglio A (2004). Immunocytochemical detection of epithelial cells in the bone marrow of primary breast cancer patients: a meta-analysis. Breast Cancer Res Treat, 87(3), 215-24. (Read full article)
54. Megale Costa LJ, Soares HP, Gaspar HA, Trujillo LG, Santi PX, Pereira RS, de Santana TL, Pinto FN, del Giglio A (2004). Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. Am J Clin Oncol, 27(3), 304-6. (Read full article)
55. Samano ES, Goldenstein PT, Ribeiro Lde M, Lewin F, Filho ES, Soares HP, del Giglio A (2004). Praying correlates with higher quality of life: results from a survey on complementary/alternative medicine use among a group of Brazilian cancer patients. Sao Paulo Med J, 122(2), 60-3. (Read full article)
56. Soares HP, Daniels S, Kumar A, Clarke M, Scott C, Swann S, Djulbegovic B, Radiation Therapy Oncology Group (2004). Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. BMJ, 328(7430), 22-4. (Read full article)
57. Fonseca FL, Soares HP, Manhani AR, Bendit I, Novaes M, Zatta SM, Arias V, Pinhal MA, Weinschenker P, del Giglio A (2002). Peripheral blood c-erbB-2 expression by reverse transcriptase-polymerase chain reaction in breast cancer patients receiving chemotherapy. Clin Breast Cancer, 3(3), 201-5. (Read full article)
58. Pereira LP, Waisberg J, Andr EA, Zanoto A, Mendes Jnior JP, Soares HP (2002). Detection of Helicobacter pylori in gastric cancer. Arq Gastroenterol, 38(4), 240-6. (Read full article)
59. Manhani AR, Manhani R, Soares HP, Bendit I, Lopes F, Nicoletti AG, Fonseca FL, Novaes M, Zatta SM, Arias V, Giralt S, del Giglio A (2001). CK-19 expression by RT-PCR in the peripheral blood of breast cancer patients correlates with response to chemotherapy. Breast Cancer Res Treat, 66(3), 249-54. (Read full article)
60. del Giglio A, Soares HP, Caparroz C, Castro PC (2001). Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer, 89(11), 2301-8. (Read full article)

Review

1. Scarini JF, Gonalves MWA, de Lima-Souza RA, Lavareze L, de Carvalho Kimura T, Yang CC, Altemani A, Mariano FV, Soares HP, Fillmore GC, Egal ESA (2024). Potential role of the Eph/ephrin system in colorectal cancer: emerging druggable molecular targets. [Review]. Front Oncol, 14, 1275330. (Read full article)
2. Naraev BG, Mailman J, Halfdanarson TR, Soares HP, Mittra ES, Hallet J (2023). Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors. [Review]. Expert Rev Anticancer Ther, 23(6), 601-615. (Read full article)
3. Chauhan A, Del Rivero J, Ramirez RA, Soares HP, Li D (2022). Treatment Sequencing Strategies in Advanced Neuroendocrine Tumors: A Review. [Review]. Cancers (Basel), 14(21). (Read full article)
4. Jacob A, Raj R, Allison DB, Soares HP, Chauhan A (2022). An Update on the Management of Mixed Neuroendocrine-Non-neuroendocrine Neoplasms (MiNEN). [Review]. Curr Treat Options Oncol, 23(5), 721-735. (Read full article)
5. Egal ESA, Jacenik D, Soares HP, Beswick EJ (2021). Translational challenges in pancreatic neuroendocrine tumor immunotherapy. [Review]. Biochim Biophys Acta Rev Cancer, 1876(2), 188640. (Read full article)
6. Hunter LA, Soares HP (2021). Quality of Life and Symptom Management in Advanced Biliary Tract Cancers. [Review]. Cancers (Basel), 13(20). (Read full article)

Editorial

1. Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR (2020). North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Pancreas, 49(6), 723-728. (Read full article)

Letter

1. Ryan CE, Saif A, Rocha F, Philip P, Hernandez JM, Ahmad S, Soares H (2022). Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors. [Letter to the editor]. Ann Surg Oncol, 30(3), 1302-1304. (Read full article)

Other

1. Loaiza-Bonilla A, Benson AB 3rd, Grothey A, Karimi M, Klempner SJ, Lin D, Mahtani R, Soares HP (2021). Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group. Oncologist (26(8), pp. 651-659). England. (Read full article)

Huntsman Cancer Institute News

• What Is Preventative Chemotherapy and How Does It Work?
• Ricky’s Ride with Neuroendocrine Pancreatic Cancer
• Ask an Expert: The Truth about Clinical Trials
• Building on the Lifesaving Work of Cancer Research
• Researcher Receives Awards for Community Contributions and Neuroendocrine Tumor Research
• Talks with Docs: Heloisa Soares, GI Oncologist

• Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
• Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
• Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
• Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
• Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
• Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
• Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
• Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
• Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
• Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
• Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide versus Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
• Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide versus Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
• Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide versus Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
• Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide versus Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
• Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide versus Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
• Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide versus Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
• Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide versus Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
• Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
• Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
• Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
• Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
• Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors
• Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors
• Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors
• Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors
• Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors
• Phase Ib/III global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro- nteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior treatment with 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu- DOTATATE/TOC) (ACTION-1)
• Phase Ib/III global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro- nteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior treatment with 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu- DOTATATE/TOC) (ACTION-1)
• Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
• Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
• Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
• Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
• Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
• Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
• Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
• Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
• Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
• Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
• Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
• Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors
• Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors
• Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors
• Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors
• Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors
• A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (I77Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)
• A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (I77Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)
• A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (I77Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)
• A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (I77Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)
• A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (I77Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)
• A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (I77Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)
• A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (I77Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)
• A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (I77Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)
• A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (I77Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)
• A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (I77Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)
• A Phase 2 Study of Iadademstat in Combination with Paclitaxel in Relapsed or Refractory Small Cell Lung Cancer and Extrapulmonary High Grade Neuroendocrine Carcinomas
• A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors
• A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors
• A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors
• NET RETREAT: A Phase II study of 177Lutetium-DOTATATE Retreatment vs. Everolimus in Metastatic/Unresectable Midgut NET
• NET RETREAT: A Phase II study of 177Lutetium-DOTATATE Retreatment vs. Everolimus in Metastatic/Unresectable Midgut NET
• NET RETREAT: A Phase II study of 177Lutetium-DOTATATE Retreatment vs. Everolimus in Metastatic/Unresectable Midgut NET
• NET RETREAT: A Phase II study of 177Lutetium-DOTATATE Retreatment vs. Everolimus in Metastatic/Unresectable Midgut NET
• NET RETREAT: A Phase II study of 177Lutetium-DOTATATE Retreatment vs. Everolimus in Metastatic/Unresectable Midgut NET
• Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative, locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1)
• Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative, locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1)
• Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative, locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1)
• Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative, locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1)